FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Approved Drugs for Infections and Infectious Diseases in Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Crofelemer

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Iliad Research and Trading

            Deal Size: $0.4 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 05, 2020

            Details:

            Transaction Proceeds Will be Allocated to Support Advancement of Regulatory Activities Associated with Jaguar's Pipeline, Including the Company's Lead Product Candidate, Crofelemer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck Animal Health

            Deal Size: $55.0 million Upfront Cash: $55.0 million

            Deal Type: Agreement February 19, 2020

            Details:

            Vecoxan joins Elanco’s previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Armistice Capital

            Deal Size: $17.5 million Upfront Cash: Undisclosed

            Deal Type: Financing January 22, 2020

            Details:

            The company intends to use the net proceeds from the registered direct offering and concurrent private placement for the commercialization of XERAVA as well as for working capital and other general corporate purposes.